RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of DXB.AX
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Volatile ride for Dimerix Limited stock price on Thursday moving between $0.410 and $0.485
(Updated on Jul 04, 2024)

Sell candidate since Jul 03, 2024 PDF

No changes to the price of Dimerix Limited stock on the last trading day (Thursday, 4th Jul 2024). During the last trading day the stock fluctuated 18.29% from a day low at $0.410 to a day high of $0.485. The price has fallen in 5 of the last 10 days and is down by -22.95% for this period.

Given the current short-term trend, the stock is expected to rise 83.85% during the next 3 months and, with a 90% probability hold a price between $0.86 and $1.32 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

DXB.AX Signals & Forecast

The volume rose on the last day while price remained unchanged. This may be an early warning and the stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Dimerix Limited stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $0.509 and $0.489. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, June 14, 2024, and so far it has fallen -27.13%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Dimerix Limited stock

Dimerix Limited finds support from accumulated volume at $0.455 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.0750 between high and low, or 18.29%. For the last week, the stock has had daily average volatility of 9.48%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (DXB.AX) For The Upcoming Trading Day Of Friday 5th

For the upcoming trading day on Friday, 5th we expect Dimerix Limited to open at $0.455, and during the day (based on 14 day Average True Range), to move between $0.425 and $0.515, which gives a possible trading interval of +/-$0.0452 (+/-9.61%) up or down from last closing price. If Dimerix Limited takes out the full calculated possible swing range there will be an estimated 19.22% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $0.455 (3.19%) than the resistance at $0.495 (5.32%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Dimerix Limited stock A Buy?

The Dimerix Limited stock holds several negative signals and despite the positive trend, we believe Dimerix Limited will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.

Current score: -4.106 Sell Candidate Upgraded

Predicted Opening Price for Dimerix Limited of Friday, July 5, 2024

Fair opening price July 5, 2024 Current price
$0.455 ( 3.19%) $0.470

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for DXB.AX

Fibonacci Support & Resistance Levels

Level Price
R3 0.530 12.77%
R2 0.501 6.67%
R1 0.484 2.90%
Price 0.470
S1 0.426 -9.29%
S2 0.409 -13.05%
S3 0.380 -19.15%

Accumulated Volume Support & Resistance Levels

Level Price
R3 0.540 14.89%
R2 0.530 12.77%
R1 0.495 5.32%
Price 0.470
S1 0.455 -3.19%
S2 0.425 -9.57%
S3 0.390 -17.02%

DXB Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Mar 08, 1999 Sep 24, 1999 May 21, 1999 $1.24 0%
2 Sep 09, 1998 Sep 18, 1998 Oct 23, 1998 $6.93 0%

FAQ

What is the symbol for Dimerix Limited Stock and on which exchange is it traded?
The symbol for Dimerix Limited is DXB.AX and it is traded on the ASX (Australian Securities Exchange).

Should I buy or sell Dimerix Limited Stock?
The Dimerix Limited stock holds several negative signals and despite the positive trend, we believe Dimerix Limited will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.

How to buy Dimerix Limited Stock?
Dimerix Limited Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Dimerix Limited Stock.

What's the current price of Dimerix Limited Stock?
As of the end of day on the Jul 04, 2024, the price of an Dimerix Limited (DXB.AX) share was $0.470.

What is the 52-week high and low for Dimerix Limited Stock?
The 52-week high for Dimerix Limited Stock is $0.665 and the 52-week low is $0.0610.

What is the market capitalization of Dimerix Limited Stock?
As of the Jul 04, 2024, the market capitalization of Dimerix Limited is 258.592M.

When is the next earnings date for Dimerix Limited?
The upcoming earnings date for Dimerix Limited is Jul 26, 2024.
Click to get the best stock tips daily for free!

About Dimerix Limited

Dimerix Limited Dimerix Limited, a clinical-stage biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. The company develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; and DMX-700 that is in pre-clinical development for chronic obstructive pulmonary disease. The company was founded in 2004 an... DXB.AX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT